Immunohistochemistry results revealed a significant decrease in VEGF (vascular endothelial growth factor) and HIF-1α (hypoxia inducible factor-1-alpha) expression, which resulted in a significant reduction of telangiectasias on the face part treated with EGCG in comparison to control (13.8% vs. 28.4% of the epidermis with erythema). The gene discussed is VEGFA; the disease is Erythema.